Author

G. P. Kim

Institutions: North Central Cancer Treatment Group, Cancer Center of Kansas, Mayo Clinic in Arizona

Observed institutions: Genentech, North Central Cancer Treatment Group, Cancer Center of Kansas, Sanofi (United States), Mayo Clinic in Arizona

OpenAlex ID: A5058114930

Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.

2011 · G. P. Kim, N. R. Foster, et al. · Journal of Clinical Oncology · 23

Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma.

2011 · G. P. Kim, N. R. Foster, et al. · Journal of Clinical Oncology · 13

Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma

2007 · G. P. Kim, A. L. Oberg, et al. · Journal of Clinical Oncology · 7

Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer

2008 · G. P. Kim, M. Haddock, et al. · Journal of Clinical Oncology · 2

Works count: 4

Citation count: 45

H-index: 3

I10-index: 2